CME-CPD Accreditation

35th International Papillomavirus Conference

17.04 – 21.04. 2023

Jointly provided by Partners for Advancing Clinical Education (PACE) and International Papillomavirus Society (IPVS)

Target Audience

The 35th International Papillomavirus Conference is the global meeting place for researchers, clinicians, and other health professionals to share knowledge and ideas on papillomaviruses and their associated diseases. Because of the diverse, clinically focused educational offering, participants are able to tailor the curriculum to meet the needs of international clinicians of all levels of experience.

Educational Objectives

Upon completion of this activity, participants should be able to:

  • Apply the latest developments in therapeutic and prophylactic vaccines
  • Diagnose and manage HPV-related non-cervical cancers
  • Analyse epidemiology and molecular biology of papillomavirus
  • Identify new technologic methods for HPV detection
  • Demonstrate different approaches for HPV screening detection
  • Identify educational resources and networks for the exchange of knowledge and learning about HPV
  • Recommend prevention of HPV-associated cancers particularly cervical cancer and other PV-associated diseases

Instructions for Credit

To receive CE credit, learners must follow these steps:

  1. Visit the IPVC 2023 online evaluation: https://www.paceducation.com/IPVC2023
  2. Enter your profile information or create a new account: https://paceducation.com/register
  3. Complete the activity evaluation
  4. Upon completion of all evaluation questions, your credit will be made available for download immediately.

For Pharmacists: Upon successfully completing the activity evaluation, your credit will be submitted to CPE Monitor. Please check your NABP account within thirty (30) days to make sure the credit has been posted.

Faculty and Disclosure of Conflicts of Interest

PACE requires planners, faculty, and others who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Disclosure information is available here: IPVC23 – Final COI. 

The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The education partner planners and others have no relevant financial relationship(s) to disclose with ineligible companies.

Program Agenda  

A program agenda with registration and break times listed can be found here.

A description of each Symposium can be found here.

Americans with Disabilities Act

Event staff will be glad to assist you with any special needs (i.e., physical, dietary, etc). Please contact Gil Orevi prior to the live event at gorevi@kenes.com.

Fee Information

Fee information can be found here.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and the International Papillomavirus Society (IPVS), PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Physician Continuing Education

PACE designates this live activity for a maximum of 39.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Breakdown  

Each participant should claim only those hours of credit that he/she actually spent in the educational activity.  

Day  Maximum Credits 
17.04

 7.5
18.04 

7 
19.04

8.5
20.04

9.5 
 21.04

 7.25
Total Credits: 

39.75 

 

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Visit 2021 website Membership